| Literature DB >> 35655653 |
Dodi Safari1, Daniel Joko Wahyono2, Wisnu Tafroji1, Anton Budhi Darmawan3, Yayah Winarti1, Wahyu Dwi Kusdaryanto3, Wisiva Tofriska Paramaiswari1, Hendro Pramono2, Meyta Pratiwi2, Muhamad Riza Chamadi2.
Abstract
Haemophilus influenzae is a Gram-negative opportunistic bacterial pathogen of the human respiratory tract. This study describes the prevalence, serotype distribution, and susceptibility profiles of H. influenzae strains isolated from the nasopharynx of school children with acute otitis media (AOM) in Banyumas Regency, Central Java, Indonesia. H. influenzae was isolated from nasopharyngeal swab specimens using chocolate agar plates supplemented with IsoVitaleX and bacitracin. Serotyping was performed using quantitative polymerase chain reaction. Antimicrobial susceptibility profiles were determined using a microdilution broth assay. H. influenzae was present in 69.7% of samples (85/122). Nontypeable H. influenzae (NHTi) was the most common serotype (95.3%), followed by H. influenzae type b (3.5%) and H. influenzae type f (1.2%). All the H. influenzae isolates were susceptible to levofloxacin, ceftriaxone, imipenem, meropenem, cefuroxime, and cefixime. Most isolates were susceptible to sparfloxacin (99%), cefepime (99%), amoxicillin/clavulanic acid 2 : 1 (99%), ampicillin/sulbactam 2 : 1 (96%), chloramphenicol (94%), tetracycline (93%), ampicillin (87%), and clarithromycin (82%). Nineteen percent of the isolates were resistant to cotrimoxazole, and 11% of the isolates were resistant to ampicillin. This study showed that H. influenzae carriage among samples was dominated by NTHi and less susceptible to cotrimoxazole.Entities:
Year: 2022 PMID: 35655653 PMCID: PMC9152372 DOI: 10.1155/2022/5391291
Source DB: PubMed Journal: Int J Microbiol
Identification and serotyping of 85 H. influenzae strains isolated from nasopharynx of school children with AOM.
| Identification | Children, n (%) |
|---|---|
| hpd detection | 85 (100) |
| Serotype: | |
| a | 0 |
| b | 3 (3.5) |
| c | 0 |
| d | 0 |
| e | 0 |
| f | 1 (1.2) |
| NTHi | 81 (95.3) |
Antimicrobial susceptibility of H. influenzae isolated from nasopharynx of school children with AOM.
| Antimicrobials | Susceptible (%) | Intermediate (%) | Resistant (%) | MIC50 ( | MIC90 ( | MIC range ( |
|---|---|---|---|---|---|---|
| LEVO | 100 | 0 | 0 | ≤0.03 | ≤0.03 | ≤0.03 to 0.5 |
| CLA | 82 | 18 | 0 | 8 | 16 | ≤0.12 to 16 |
| FAC | 96 | 1 | 2 | ≤4 | 8 | ≤4 to >16 |
| AXO | 100 | 0 | 0 | ≤0.03 | ≤0.03 | ≤0.03 to 0,25 |
| AMPa | 86 | 4 | 11 | 0,25 | 4 | ≤0.12 to >4 |
| FEP | 99 | 0 | 1 | ≤0.12 | 0,25 | ≤0.12 to >2 |
| SPX | 99 | 0 | 1 | ≤0.03 | ≤0.03 | ≤0.03 to 0,5 |
| IMI | 100 | 0 | 0 | ≤0.5 | ≤0.5 | ≤0.5 to 1 |
| SXT | 74 | 7 | 19 | 0.25/4.75 | >2/38 | ≤0.06/1.19 to >2/38 |
| MERO | 100 | 0 | 0 | ≤0.06 | ≤0.06 | ≤0.06 to 0,25 |
| FUR | 100 | 0 | 0 | 1 | 2 | ≤0.5 to 4 |
| FIX | 100 | 0 | 0 | ≤0.12 | ≤0.12 | ≤0.12 to 1 |
| TET | 93 | 1 | 6 | 0,5 | 1 | ≤0.25 to >4 |
| CHL | 94 | 0 | 6 | ≤0.5 | 1 | ≤0.5 to >4 |
| A/S2 | 96 | 0 | 4 | ≤1/0.5 | ≤1/0.5 | ≤1/0.5 to >2/1 |
| AMC | 99 | 0 | 1 | ≤2/1 | ≤2/1 | ≤2/1 to >16/8 |
aBreakpoints used for ampicillin: susceptible = ≤1, intermediate = 2, resistant = ≥4. LEVO, levofloxacin; CLA, clarithromycin; FAC, cefaclor; AXO, ceftriaxone; AMP, ampicillin; FEP, cefepime; SPX, sparfloxacin; IMI, imipenem; SXT, trimethoprim/sulfamethoxazole; MERO, meropenem; FUR, cefuroxime; FIX, cefixime; TET, tetracycline; CHL, chloramphenicol; A/S2, ampicillin/sulbactam (2 : 1); AMC, amoxicillin/clavulanic acid (2 : 1).
Antibiogram of ampicillin nonsusceptible isolates of H. influenzae isolated from nasopharynx of school children with AOM.
| Lab ID | Serotypes | CLA | AMP | A/S2 | AMC | AXO | FEP | FUR | FIX | FAC | Grouping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OMP090 | NT | S | R | S | S | S | S | S | S | S | BLNAR |
| OMP094 | NT | S | R | S | S | S | S | S | S | S | BLNAR |
| OMP099 | NT | S | R | R | S | S | S | S | S | S | BLNASR |
| OMP110 | NT | S | R | S | S | S | S | S | S | R | BLNAR |
| OMP124 | NT | S | I | S | S | S | S | S | S | I | BLNAI |
| OMP141 | Hi f | S | I | S | S | S | S | S | S | S | BLNAI |
| OMP151 | NT | I | R | S | S | S | S | S | S | S | BLNAR |
| OMP0158 | NT | S | R | R | S | S | S | S | S | S | BLNASR |
| OMP0161 | NT | S | R | S | S | S | S | S | S | S | BLNAR |
| OMP0179 | NT | S | R | S | S | S | S | S | S | S | BLNAR |
| OMP0200 | NT | S | R | R | S | S | S | S | S | R | BLNASR |
| OMP0119 | NT | S | I | S | S | S | S | S | S | S | BLNAI |
FAC, cefaclor; CLA, clarithromycin; AXO, ceftriaxone; AMP, ampicillin; FEP, cefepime; FUR, cefuroxime; FIX, cefixime; A/S2, ampicillin/sulbactam (2:1); AMC, amoxicillin/clavulanic acid (2:1). S, susceptible; I, intermediate; R, resistant. BLNAR: β-lactamase-nonproducing ampicillin-resistant, BLNASR: β-lactamase-nonproducing ampicillin/sulbactam resistant, BLNAI: β-lactamase-nonproducing ampicillin intermediate resistant.